PriceTargets.com logo

IO Biotech - IOBT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 301.46%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.74 As of 02/7/2023 01:00 AM ET
▲ +0.09 (3.40%)

This chart shows the closing price for IOBT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IO Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IOBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IOBT

Analyst Price Target is $11.00
▲ +301.46% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for IO Biotech in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 301.46% upside from the last price of $2.74.

This chart shows the closing price for IOBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in IO Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Morgan StanleyLower TargetOverweight$15.00 ➝ $11.00Low
11/21/2022HC WainwrightInitiated CoverageBuyLow
11/30/2021Morgan StanleyInitiated CoverageOverweight$21.00High
11/30/2021Jefferies Financial GroupInitiated CoverageBuy$20.00Medium
11/30/2021CowenInitiated CoverageOutperformMedium
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/10/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/9/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
IO Biotech logo
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More

Today's Range

Now: $2.74
Low: $2.60
High: $2.87

50 Day Range

MA: $2.67
Low: $2.30
High: $3.00

52 Week Range

Now: $2.74
Low: $2.15
High: $9.77

Volume

13,794 shs

Average Volume

116,676 shs

Market Capitalization

$78.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of IO Biotech?

The following sell-side analysts have issued reports on IO Biotech in the last year: HC Wainwright, and Morgan Stanley.
View the latest analyst ratings for IOBT.

What is the current price target for IO Biotech?

1 Wall Street analysts have set twelve-month price targets for IO Biotech in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 283.3%. Morgan Stanley has the highest price target set, predicting IOBT will reach $11.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $11.00 for IO Biotech in the next year.
View the latest price targets for IOBT.

What is the current consensus analyst rating for IO Biotech?

IO Biotech currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IOBT will outperform the market and that investors should add to their positions of IO Biotech.
View the latest ratings for IOBT.

What other companies compete with IO Biotech?

Other companies that are similar to IO Biotech include Longeveron, NuCana, Impel Pharmaceuticals, Adagene and Assembly Biosciences. Learn More about companies similar to IO Biotech.

How do I contact IO Biotech's investor relations team?

The company's listed phone number is 45-7070-2980. The official website for IO Biotech is www.iobiotech.com. Learn More about contacing IO Biotech investor relations.